Public Companies
Field Trip Health & Wellness To Webcast Live at the KCSA Mental Health Conference on December 15th
Field Trip Health & Wellness Ltd. (TSXV: FTHW), a global leader in the delivery of psychedelic therapies, today announced that Ronan Levy, Chairman…
Field Trip Health & Wellness Ltd. (TSXV: FTHW), a global leader in the delivery of psychedelic therapies, today announced that Ronan Levy, Chairman & Chief Executive Officer of Field Trip Health & Wellness, will webcast live at the KCSA Mental Health Conference, hosted by VirtualInvestorConferences.com, on Thursday, December 15th, 2022.
DATE: December 15, 2022
TIME: 11:00 a.m. ET
LINK: https://bit.ly/3Ub0iE3
A recording of the webcast presentation will be available on the Events and Presentations section of Field Trip’s investor relations website following the events.
The Field Trip management team will also participate in one-on-one investor meetings following the conference. For institutional investors to schedule a meeting, please contact fieldtripIR@kcsa.com.
Recent Company Highlights
- Provided a business update and reported fiscal second quarter 2023 results.
- Launched Freedom by Field Trip™, a first-of-its-kind one-year hybrid ketamine therapy program that blends the power of psychedelic-assisted therapies with holistic wellness support.
- Announced the relaunch and refresh of its award-winning psychedelic app, now named Field Trip.
- Strengthened leadership team with two executive appointments.
About Field Trip Health & Wellness Ltd
With a large global community of psychedelic-interested people, proprietary psychedelic therapies that generate transformative results for people in the treatment of mental health conditions and a brand and share of voice that is reaching millions of people, Field Trip is a center of gravity for the psychedelic renaissance.
-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Law & Regulation1 week ago
Tryp Therapeutics, Exopharm merger approved by shareholders
-
Law & Regulation1 week ago
Adastra reports record sales in 2023, but remains in the red
-
Psychedelics1 week ago
MindBio Landmark Sleep Research Published in Prestigious Nature Portfolio Journal Translational Psychiatry
-
LSD1 week ago
The First Wave of Blotter Acid Inspired Trippy Psychedelic Art